The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...

The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.

AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The 340B Drug Pricing Program entitles participating hospitals and clinics (called covered entities) to purchase outpatient drugs at a substantial discount from manufacturers. Covered entities either ...

On July 31, 2025, the Health Resources and Services Administration (“HRSA”) announced the availability of a voluntary 340B Rebate Model Pilot Program (the “340B Rebate Pilot” or the “Pilot”) that ...

For the 5,000 people in Illinois living with sickle cell disease, access to affordable medical care and life-saving treatments is necessary. Yet far too many still struggle to get the medications and ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

An obscure, supposedly free federal program is blowing a hole in state budgets – by depriving state governments of billions in corporate tax revenue and inflating costs for their public employee ...